Really excited about this line of research, and it’s also very cool that you are publishing this research plan overview in advance :)
Some random thoughts:
In many contexts (say, evidence-backed global development interventions) I expect the top interventions to be picked up to the point of no more room for funding. We see this, for example, with many highly cost-effective vaccines funded by the Gates Foundation or WHO.
This would likely affect the marginal cost-effectiveness distribution.
It might make sense to model the total cost-effectiveness, rather than the marginal cost-effectiveness.
I think it’d make sense to model the interventions’ cost-effectiveness separately from charities’ cost-effectiveness.
Maybe there is interesting work examining ROI distribution.
I’m not sure how the maximum entropy prior fits into this, but this seems like an interesting approach.
Really excited about this line of research, and it’s also very cool that you are publishing this research plan overview in advance :)
Some random thoughts:
In many contexts (say, evidence-backed global development interventions) I expect the top interventions to be picked up to the point of no more room for funding. We see this, for example, with many highly cost-effective vaccines funded by the Gates Foundation or WHO.
This would likely affect the marginal cost-effectiveness distribution.
It might make sense to model the total cost-effectiveness, rather than the marginal cost-effectiveness.
I think it’d make sense to model the interventions’ cost-effectiveness separately from charities’ cost-effectiveness.
Maybe there is interesting work examining ROI distribution.
I’m not sure how the maximum entropy prior fits into this, but this seems like an interesting approach.